Information Provided By: 
Fly News Breaks for December 13, 2018
AZN
Dec 13, 2018 | 16:49 EDT
SunTrust analyst John Boris initiated AstraZeneca with a Buy rating and $48 price target, saying oncology should fuel growth through 2022 -- supported by label expansion of its in-line products and new launches -- as well as growth accelerated by 2019 pipeline catalysts.
News For AZN From the Last 2 Days
AZN
Apr 23, 2024 | 11:16 EDT
Bearish flow noted in AstraZeneca with 3,362 puts trading, or 1.7x expected. Most active are 4/26 weekly 70 puts and May-24 70 calls, with total volume in those strikes near 3,600 contracts. The Put/Call Ratio is 1.72, while ATM IV is up nearly 2 points on the day. Earnings are expected on April 25th.
